Using this highly sensitive assay (0.05%), we have shown that PIK3CA hotspot mutations are present at a relatively high frequency in the EpCAM‐positive CTC fraction not only in patients with metastatic but with early BrCa as well. Here, EPCAM is linked to invasive breast carcinoma.